Key Developments: EntreMed Inc (ENMD.W)
1.82USD
17 May 2013
$0.01 (+0.55%)
$1.81
$1.82
$1.82
$1.82
100
56
$3.25
$1.33
Latest Key Developments (Source: Significant Developments)
EntreMed Inc Announces CEO Appointment
EntreMed Inc announced that Ken K. Ren, Ph.D. has been appointed Chief Executive Officer, after having completed his one-year term as interim CEO. Full Article
EntreMed Inc Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
EntreMed Inc announced the initiation of a single-center Phase 2 study entitled A Phase 2 Study of Oral ENMD-2076 Administered to Patients with Advanced/Metastatic Soft Tissue Sarcoma at Princess Margaret Hospital where the study is led by Malcolm Moore, MD and Albiruni R.A. Razak, MD. Full Article
EntreMed Inc Files New Drug Clinical Trial Application For ENMD-2076 With China SFDA To Advance Global Development Strategy
EntreMed Inc announced that it has submitted a new drug clinical trial application with China 's State Food and Drug Administration (SFDA) for its drug candidate, ENMD-2076, to conduct global clinical trials in triple-negative breast cancer patients. Full Article
EntreMed Inc Announces Initiation Of Second Site For Phase 2 Trial In Triple-Negative Breast Cancer
EntreMed Inc announced the initiation of a second site for its Phase 2 study of ENMD-2076 in triple-negative breast cancer (TNBC). Kathy Miller, MD, Associate Professor at the Melvin and Bren Simon Cancer Center at Indiana University serves as the investigator for the study. Indiana University joins the University of Colorado Cancer Center where the Phase 2 study is already underway. Full Article
EntreMed Inc Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
EntreMed Inc announced the publication of favorable results of a preclinical study in breast cancer of oral Aurora A/angiogenic kinase inhibitor, ENMD-2076. In the study, a diverse panel of twenty-nine breast cancer cell lines representative of the clinically defined breast cancer subtypes were exposed to ENMD-2076 and the effects on proliferation, apoptosis, and cell cycle distribution were evaluated. ENMD-2076 demonstrated more robust activity against cell lines of the TNBC subtype compared to the luminal and HER2-amplified subtypes. This in vitro activity was confirmed in vivo, in MDA-MB-468 and MDA-MB-231 TNBC xenografts. Baseline gene expression profiling and pathway analysis of the panel revealed that p53 and G1/S cell cycle pathways were upregulated in the more sensitive cell lines. Within the TNBC subset itself, cell lines with a p53 mutation and increased p53 expression were more sensitive to the cytotoxic and pro-apoptotic effects of ENMD-2076 exposure than cell lines with decreased p53 expression. This information provides the basis for a predictive biomarker strategy to explore in future clinical trials with ENMD-2076. Full Article
EntreMed Inc Announces Initiation Of Phase 2 Trial In Triple-Negative Breast Cancer
EntreMed Inc announced the initiation of a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer. Jennifer R. Diamond, MD at the University of Colorado serves as the principal investigator for the study. The study is sponsored by EntreMed and is supported by a grant from the National Cancer Institute. Full Article
EntreMed, Inc. Appoints Interim Chief Executive Officer
EntreMed, Inc. announced that the Company has appointed Dr. Ken K. Ren as interim Chief Executive Officer, effective as of April 2, 2012. Full Article
EntreMed, Inc. Announces Board Changes
EntreMed, Inc. announced that Wei-Wu He, Ph.D has joined the Board of Directors as Executive Chairman and Tak W. Mak, Ph.D has joined as a member of the Board of Directors. Full Article
EntreMed, Inc. Secures USD10 Million Strategic Financing
EntreMed, Inc. announced that it has secured USD10 million in financing with strategic accredited investors, including IDG-Accel China Growth Fund II L.P. (IDG), Emerging Technology Partners, LLC (ETP), and Dr. Tak W. Mak, Director of The Campbell Family Institute for Cancer Research. The Company entered into purchase agreements with the investors, pursuant to which the Company has agreed to issue and sell to the investors convertible notes in the aggregate principal amount of USD10 million. The investors also will be issued warrants covering a number of shares of common stock equal to 20% of the principal amount of the notes, divided by USD1.15. The warrants are exercisable at USD1.40 per share. The closing of the transaction is anticipated to occur on or about January 27, 2012 upon the satisfaction of certain conditions. Full Article
EntreMed, Inc.'s ENMD-2076 Demonstrates Promising Activity In A Phase 2 Study In Platinum-Resistant Ovarian Cancer Patients
EntreMed, Inc. announced the final data for the primary endpoint of progression free survival rate at 6 months for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients. Data from all 64 patients showed a six-month progression free survival rate of 22% Four patients achieved a partial response as measured by RECIST v1.1. Median overall survival has not yet been reached. The side effect profile was consistent with activity against ENMD-2076's targets, in particular, VEGFR2 and Aurora A. The study was conducted at 6 major cancer centers across the United States and Canada and the subject of a presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting held June 3 - 7, 2011 in Chicago, Illinois. The study was an open-label, single-arm, multi-center-study of 64 patients receiving ENMD-2076 dosed orally as a single agent in patients with platinum-resistant recurrent ovarian, peritoneal or tubal cancer. The primary endpoint for the study was progression-free survival rate at six months. Secondary end-points include safety, response rate, duration of response, and overall survival. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
